SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.

Hadoux, Julien

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. [electronic resource] - International journal of cancer Dec 2014 - 2711-20 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1097-0215

10.1002/ijc.28913 doi


Adrenal Gland Neoplasms--drug therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating--therapeutic use
Biomarkers, Tumor--genetics
Brain Neoplasms--drug therapy
DNA Methylation
DNA Modification Methylases--genetics
DNA Repair Enzymes--genetics
Dacarbazine--analogs & derivatives
Female
Follow-Up Studies
Humans
Male
Middle Aged
Mutation--genetics
Neoplasm Metastasis
Neoplasm Staging
Paraganglioma--drug therapy
Pheochromocytoma--drug therapy
Polymerase Chain Reaction
Prognosis
Promoter Regions, Genetic--genetics
Retrospective Studies
Succinate Dehydrogenase--genetics
Survival Rate
Temozolomide
Tumor Suppressor Proteins--genetics